EPAS1 and hepatocellular carcinoma: For example, miR-383-5p inhibited tumor cell mobility through regulating EPAS1 in lung cancer cells28–31, the decrease of miR-383-5p is suggested as a potential independent biomarker for poor prognosis in intestinal subtype of gastric cancer26, and the rescue of miR-383-5p expression in HCC cells prompted a better response outcome by the sorafenib targeting therapy32.